Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
April 30, 2024 07:05 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half...
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 22, 2024 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration...
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
October 31, 2023 07:30 ET
|
Harmony Biosciences
Continued Strong Growth with WAKIX® (pitolisant) Net Revenue of $160.3 Million for Third Quarter 2023; Increased ~37% Year-over-Year Average Number of Patients on WAKIX Increased by ~350...
Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates
August 01, 2023 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue Increased ~25% Year-over-Year to $134.2 Million for Second Quarter 2023 Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,450 for Second Quarter...
Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates
May 02, 2023 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue Increased ~40% Year-over-Year to $119.1 Million for First Quarter 2023 Average Number of Patients on WAKIX Increased ~1,200 Year-over-Year to ~5,100 for First Quarter...
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 21, 2023 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue Increased ~41% Year-over-Year to $128.3 Million for Fourth Quarter 2022; ~43% to $437.9 Million for Full Year 2022 Achieved Net Income of $181.5 Million for Full Year...
Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates
November 01, 2022 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue of $117.2 Million for Third Quarter 2022 Increase of ~45% vs. the Same Period in 2021 Average Number of Patients on WAKIX Increased to ~4,600 Prader-Willi Syndrome...
Harmony Biosciences Reports Second Quarter 2022 Financial Results and Business Updates
August 02, 2022 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue of $107.0 Million for Second Quarter 2022 Increase of 45% vs. the Same Period in 2021 Average Number of Patients on WAKIX Increased to ~4,300 Signs New Agreement with...
Harmony Biosciences Reports First Quarter 2022 Financial Results and Business Updates
May 03, 2022 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue of $85.3 Million for First Quarter 2022 Increase of 43% vs. the Same Period in 2021 WAKIX Surpasses $500 Million in Cumulative Net Revenue Since Launch Initiated...
Harmony Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
February 28, 2022 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue Increased 62% Year-over-Year to $91.2 Million for Fourth Quarter 2021 and 91% to $305.4 Million for Full Year Achieved First Full Year of Profitability and Net income...